Cobenfy Ad Letter Signals Tight Limits on DTC Claims: Attorneys
FDA’s latest enforcement action against a schizophrenia drug advertisement offers a pointed reminder of how narrowly the agency continues to interpret permissible direct-to-consumer claims, according to regulatory attorneys reviewing the case. A 12/15 Notice of Violation letter describes the TV ad produced by Bristol Myers Squibb’s Karuna Therapeutics unit for its Cobenfy (xanomeline and trospium chloride) capsules as overstating clinical evidence, implying unstudied benefits, and using visuals that distracted from risk disclosures. A Sheppard Mullin legal analysis says the letter reinforces several recurring themes that companies should heed as FDA maintains pressure on consumer drug promotion.
One of the central lessons, attorneys say, is FDA’s continued insistence that promotional claims align precisely with how clinical trials were designed and analyzed. While Cobenfy’s studies showed improvement on a composite schizophrenia rating scale, FDA objected to messaging that appeared to promise improvement in specific symptom domains, such as negative symptoms.
According to the analysis, FDA remains skeptical of post hoc interpretations of composite endpoints and expects claims about discrete symptom groups to be supported by prospectively designed trials or data the agency considers sufficiently robust. Absent that level of evidence, FDA is unlikely to accept marketing that extrapolates broader or more granular benefits from overall efficacy results.
The letter also underscores how closely FDA examines language that could suggest use in patient populations not studied, even when the implication is subtle. In this case, FDA took issue with the ad’s suggestion that patients who “still” experience symptoms might benefit from the drug, interpreting that phrasing as an implied claim of effectiveness in treatment-resistant schizophrenia, the analysis says.
Attorneys note that FDA has consistently rejected promotional language that could be read as positioning a product for patients who have failed other therapies, unless comparative or refractory-population data clearly support such claims. The takeaway, they say, is that even common, conversational phrasing can trigger enforcement if it hints at broader efficacy than the label allows.
Finally, the letter reinforces FDA’s ongoing concern that high-impact visuals can undermine risk communication. Attorneys point out that FDA continues to view distracting imagery as a compliance issue, not a stylistic one, particularly when such visuals appear during the major statement of risks.
Taken together, the lawyers conclude, the enforcement action reflects FDA’s broader message to industry: promotional claims must be tightly tied to trial design and labeling, implied benefits will be read expansively by regulators, and neither disclaimers nor creative production choices will offset what the agency views as unsupported messaging.
As FDA sustains its focus on direct-to-consumer advertising, the analysis suggests companies should expect continued enforcement grounded in these same principles.